Acute Respiratory Disease Syndrome

Mesenchymal Stem Cells (MSCs) are being studied in acute respiratory distress syndrome (ARDS), with research exploring their potential to modulate inflammation and support lung repair. 

ARDS is a life-threatening condition characterized by extensive lung inflammation, most often triggered by severe infections, trauma, or other critical illnesses. It causes serious breathing difficulties and continues to carry a high risk of mortality. Current treatment options are mainly supportive, including mechanical ventilation, as no specific curative therapy exists. 

Ongoing MSC studies investigate both immune-regulating and tissue-repair processes in the lungs. Although findings remain preliminary, this line of research contributes to the broader scientific effort to develop new strategies in respiratory and critical care medicine. 

Clinical Trials


Umbilical cord mesenchymal stromal cells as critical COVID-19 adjuvant therapy: A randomized controlled trial — Ismail Hadisoebroto Dilogo, et al.



Umbilical cord mesenchymal stem cells for COVID-19 acute respiratory distress syndrome: A double-blind, phase 1/2a, randomized controlled trial — Giacomo Lanzoni , et al.



Treatment of COVID-19-associated ARDS with mesenchymal stromal cells: a multicenter randomized double-blind trial — Antoine Monsel, et al.



Mesenchymal stem cells derived from perinatal tissues for treatment of critically ill COVID-19-induced ARDS patients: a case series — Seyed-Mohammad Reza Hashemian, et al.



Safety and long-term improvement of mesenchymal stromal cell infusion in critically COVID-19 patients: a randomized clinical trial — Carmen Lúcia Kuniyoshi Rebelatto, et al.



Mesenchymal stromal cell therapy for COVID-19-induced ARDS patients: a successful phase 1, control-placebo group, clinical trial — Najmeh Kaffash Farkhad, et al.



Human Umbilical Cord-Derived Mesenchymal Stem Cells for Acute Respiratory Distress Syndrome — Hon-Kan Yip, et al.



The Systematic Effect of Mesenchymal Stem Cell Therapy in Critical COVID-19 Patients: A Prospective Double Controlled Trial — G Adas, et al.